Health ❯ Healthcare ❯ Drug Development

Clinical Research

Phase 3 Trials Patient Enrollment Efficacy Studies Phase 2 Trials Eli Lilly Lynozyfic Therapeutic Advances Genetic Studies Efficacy and Safety Studies Phase 3 Studies Antifungal Agents Phase Trials Patient Safety PIPI Drugs Nebulized Therapies Alzheimer's Treatments SpringWorks Therapeutics Experimental Drugs Cancer Risk Regulatory Approval Fabhalta Eli Lilly Trials Povetacicept ALXN1840 WVE-007 Laboratory Practices VK2735 Semaglutide Peptide Inhibitors Pharmaceutical Companies Oncology Alzheimer's Focus Mental Health Treatments GLP-1 Treatments Therapeutics Phase 1 Studies AstraZeneca Studies

Enzyme Platform Produces Promising, Less-Toxic Polyene Candidate Nys34

Researchers used genome mining with enzyme-guided sugar addition and amidation to make polyenes more soluble and potent.

ETH Zurich Pins GRK2 Aggregation as Alzheimer’s Target and Reveals 'Compound 10' That Slows Decline in Mice

Legend Biotech Q1 Sales Jump on CARVYKTI Growth Despite Expansion-Related Margin Hit

FDA Authorizes Early Access to Daraxonrasib for Pancreatic Cancer Patients

FDA Launches First Real-Time Clinical Trial Pilot With AstraZeneca and Amgen

Karyopharm Raises $30 Million in RA Capital Private Placement

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

Alveus Therapeutics Launches With $159.8 Million Series A to Advance Next‑Generation Obesity Drugs

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

FDA Grants Breakthrough Therapy Designation to Incyte’s CALR‑Targeting Antibody as ASH Data Show Early Efficacy in Myelofibrosis

Junshi’s Subcutaneous Toripalimab Matches IV in Phase 3 NSCLC Trial as Company Prepares NDA

Novartis’ Fabhalta Slows Kidney Function Decline in Final Phase 3 IgAN Results

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials